CytoDyn Inc. (CYDY) Plans to File IND for Clinical Trial of PRO 140 in Colon Carcinoma Patients following Significant Preclinical Results
PRO 140 has been shown effective in inhibiting the growth of a human colon carcinoma cell line (SW480) in a prominent mouse model PRO 140 extended the lives of treated mice and reduced tumor growth by more than 50 percent CytoDyn was recently featured favorably in a report by a leading independent small cap media portal Biotechnology company CytoDyn Inc. (OTCQB: CYDY) recently announced exciting progress (http://ibn.fm/thpLl) in the development of PRO 140 (leronlimab), its novel humanized CCR5 monoclonal antibody, which has multiple therapeutic indications including treating HIV, cancer and inflammatory conditions. In preclinical studies conducted over the past year,…